Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice

Published:2015-08-12 Issue:2 Volume:55 Page:210-220
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:Rheumatology

Author:

Schaeverbeke Thierry,Truchetet Marie-Elise,Kostine Marie,Barnetche Thomas,Bannwarth Bernard,Richez Christophe

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

http://academic.oup.com/rheumatology/article-pdf/55/2/210/5157423/kev277.pdf

Reference67 articles.

1. Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE

2. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

3. Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

4. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor blockers can make sense

5. Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug survival analysis of etanercept compared with monoclonal antibody tumour necrosis factor-α inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a propensity score-matched analysis from the Czech ATTRA registry;Scandinavian Journal of Rheumatology;2024-08-06

2. A Canadian Retrospective Chart Review Evaluating Concomitant Methotrexate De-escalation Patterns in Patients with Rheumatoid Arthritis Treated with Biologic or Targeted Synthetic DMARDs;Rheumatology and Therapy;2024-07-08

3. Predictors of tumor necrosis factor inhibitors primary failure in rheumatoid arthritis patients;Egyptian Rheumatology and Rehabilitation;2024-05-30

4. Enhancing the Efficacy and Safety of Methotrexate Treatment: A Focus on Drug Interactions (Review);Safety and Risk of Pharmacotherapy;2024-04-27

5. Modern ideas about the etiopathogenesis of rheumatoid arthritis;Azerbaijan Journal of Physiology;2023-12-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3